Dr. Michael J. Quadrini, MD

Dr. Quadrini practices at Nephrology Consultants in Huntsville, Alabama.

Dr. Quadrini's NPI, 1831258698, was assigned on December 7, 2006. Dr. Quadrini graduated from Northwestern University Feinberg Medical School in 2002. Dr. Quadrini holds Tennessee license 39862.

Dr. Quadrini's primary practice is Nephrology Consultants, at 2780 Bob Wallace SW Ave, Huntsville, AL 35805 in Madison County. The practice phone is (256) 533-4626.

Dr. Quadrini's primary practice is Nephrology Consultants in Huntsville, Alabama. Dr. Quadrini is also affiliated with Huntsville Hospital. The medical group on file is Nephrology Consultants, LLC. Dmand AI also links Dr. Quadrini to 4 more hospitals, 5 dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Quadrini practices, 11 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Quadrini's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Quadrini's licenses on file in 2 states: Tennessee and Alabama.

CMS data shows 2,044 Medicare services from Dr. Quadrini across 13 procedure codes in 2024, for 532 Medicare patients. Medicare paid $148,924 for them.

CMS counts 532 Medicare patients who saw Dr. Quadrini in 2024. The largest group is 75 to 84, with 201 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 16% are also on Medicaid. Their average risk score is 3.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Quadrini's median patient age at 73, with 46% women.

In 2024, Dr. Quadrini wrote 1,199 Medicare Part D claims for 185 patients. 85% of them were for generic drugs. CMS names the drug for 1,070 of them, across 33 drugs with 11 or more claims each, at $259,035 in total drug cost. In 2023, CMS named 1,042 claims across 34 drugs.

Dr. Quadrini accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Quadrini to 2 clinical trials, 2 of them phase 3 studies. Conditions studied include Polycystic Kidney, Autosomal Dominant, Nephritis, Hereditary and Polycystic Kidney Diseases. Biogen sponsors the most, 2. Open Payments lists research payments to Dr. Quadrini that name 2 trials.

CMS Open Payments shows 1,171 general payments to Dr. Quadrini from 37 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 85% of the total. Amgen Inc. paid the most, $311,040. It also lists 5 research payments totaling $151,824 from 2024 to 2025, naming 2 clinical trials.

Dr. Quadrini graduated from Northwestern University Feinberg Medical School in 2002.